[go: up one dir, main page]

ATE423547T1 - N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform - Google Patents

N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Info

Publication number
ATE423547T1
ATE423547T1 AT97945550T AT97945550T ATE423547T1 AT E423547 T1 ATE423547 T1 AT E423547T1 AT 97945550 T AT97945550 T AT 97945550T AT 97945550 T AT97945550 T AT 97945550T AT E423547 T1 ATE423547 T1 AT E423547T1
Authority
AT
Austria
Prior art keywords
phosphatidylethanolamine
acyl
active ingredient
liposome form
ingredient dosage
Prior art date
Application number
AT97945550T
Other languages
English (en)
Inventor
Paul Meers
Tong Shangguan
Shaukat Ali
Andrew Janoff
Charles Pak
Original Assignee
Transave Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transave Inc filed Critical Transave Inc
Application granted granted Critical
Publication of ATE423547T1 publication Critical patent/ATE423547T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT97945550T 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform ATE423547T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2855796P 1996-10-15 1996-10-15

Publications (1)

Publication Number Publication Date
ATE423547T1 true ATE423547T1 (de) 2009-03-15

Family

ID=21844115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97945550T ATE423547T1 (de) 1996-10-15 1997-10-15 N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform

Country Status (13)

Country Link
US (2) US6120797A (de)
EP (1) EP0966267B1 (de)
AT (1) ATE423547T1 (de)
AU (1) AU725257B2 (de)
CA (1) CA2276269C (de)
DE (1) DE69739277D1 (de)
ES (1) ES2321769T3 (de)
HU (1) HUP0000522A3 (de)
IL (1) IL130822A (de)
NO (1) NO993257L (de)
NZ (2) NZ514133A (de)
SK (1) SK283760B6 (de)
WO (1) WO1998016199A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2198854B1 (de) 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Retardierte Freisetzung Liposomaler Anesthetischer Zusammensetzungen
WO1999025319A1 (en) 1997-11-14 1999-05-27 Depotech Corporation Production of multivesicular liposomes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP2002520120A (ja) 1998-07-17 2002-07-09 スカイファーマ インコーポレーテッド 封入物質の制御放出のための生分解性組成物
KR100777647B1 (ko) 1998-08-19 2007-11-19 스키에파마 캐나다 인코포레이티드 프로포폴의 수용성 주사용 분산액
CA2443644A1 (en) * 2001-04-04 2003-01-16 Elan Corporation, Plc Genetic analysis of peyers's patches and m cells and methods and compositions targeting peyer's patches and m cell receptors
EP1395243A2 (de) * 2001-05-31 2004-03-10 SkyePharma Inc. Verkapselung von nanosuspensionen in liposomen und mikrosphärulen
WO2003047499A2 (en) 2001-12-04 2003-06-12 Ben Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
EP1471885A4 (de) * 2002-01-09 2009-04-22 Transave Inc Wirkungsvolle liposom-verkapselung
EP1474107A4 (de) * 2002-01-09 2010-01-20 Transave Inc Wirkungsvolle liposomen-verkapselung unter milden bedingungen
CA2472462A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
CA2475630C (en) * 2002-02-12 2011-01-18 Hunza Di Pistolesi Elvira & C. S.A.S. N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
EP1536843B1 (de) * 2002-07-02 2010-12-22 Board Of Regents, The University Of Texas System Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren
ITMI20021455A1 (it) * 2002-07-02 2004-01-02 Ugo Raffaello Citernesi Formulazioni fosfolipidiche di lexitropsine loro preparazione ed impiego terapeutico
CN103143031A (zh) * 2003-07-31 2013-06-12 得克萨斯大学体系董事会 用于治疗、预防和/或改善癌症、癌症发病或癌症症状的组合物和方法
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ITMI20041280A1 (it) * 2004-06-24 2004-09-24 Hunza Di Pistolesi Elvira & C Preparazione farmaceutiche dietetiche e-o cosmetiche per il trattamento dell'obesita' dell'alopecia della cellulite e dell'invecchiamento cutaneo
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20070191272A1 (en) * 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
AU2006332340B2 (en) 2005-12-30 2013-09-26 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
WO2008030818A2 (en) * 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
JP2010513354A (ja) * 2006-12-19 2010-04-30 ノヴォソム アクチェンゲゼルシャフト トランスフェクションエンハンサー要素を含む脂質および脂質集合体
AU2008287340A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN102066388A (zh) * 2008-07-08 2011-05-18 奇米股份公司 用于生产n-酰基-磷脂酰-乙醇胺的方法
CN116925238A (zh) 2009-02-03 2023-10-24 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
NZ596778A (en) 2009-06-08 2013-11-29 Amunix Operating Inc Glucose-regulating polypeptides and methods of making and using same
ES2643641T3 (es) 2009-06-08 2017-11-23 Amunix Operating Inc. Polipéptidos de hormona del crecimiento y métodos de producción y uso de los mismos
US9062299B2 (en) 2009-08-24 2015-06-23 Amunix Operating Inc. Coagulation factor IX compositions and methods of making and using same
WO2011024172A2 (en) * 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
US20130273561A1 (en) * 2010-10-29 2013-10-17 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
HRP20190454T1 (hr) 2012-02-15 2019-05-03 Bioverativ Therapeutics Inc. Rekombinantni faktor viii proteini
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
CA2943190A1 (en) 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
IL286493B (en) 2015-11-06 2022-07-01 Memorial Sloan Kettering Cancer Center Triterpene saponin analogues, methods of producing same, compositions comprising same and uses thereof
CN110023308A (zh) * 2016-10-13 2019-07-16 卡诺有限责任公司 N-酰基乙醇酰胺衍生物和其用途
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CN110869507A (zh) 2017-05-08 2020-03-06 旗舰先锋创新V股份有限公司 促进膜融合的组合物和其用途
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
MA52630A (fr) 2018-05-18 2021-05-26 Bioverativ Therapeutics Inc Procédés de traitement de l'hémophilie a
WO2021263058A1 (en) 2020-06-25 2021-12-30 Amunix Pharmaceuticals, Inc. Her-2 targeted bispecific compositions and methods for making and using the same
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4415713A1 (de) 2021-10-14 2024-08-21 Pacira Pharmaceuticals, Inc. Bupivacain-multivesikuläre liposomformulierungen und verwendungen davon
JP2025509460A (ja) 2022-03-14 2025-04-11 ファイザー・インク アジュバントを生産するための方法
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
CA1338702C (en) * 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents

Also Published As

Publication number Publication date
EP0966267A1 (de) 1999-12-29
NO993257D0 (no) 1999-06-30
HUP0000522A1 (hu) 2000-09-28
HUP0000522A3 (en) 2000-10-30
SK99399A3 (en) 2000-06-12
EP0966267A4 (de) 2006-02-01
WO1998016199A1 (en) 1998-04-23
CA2276269C (en) 2008-09-02
IL130822A (en) 2005-12-18
US6294191B1 (en) 2001-09-25
NZ514133A (en) 2001-09-28
CA2276269A1 (en) 1998-04-23
SK283760B6 (sk) 2004-01-08
US6120797A (en) 2000-09-19
NZ336538A (en) 2001-11-30
IL130822A0 (en) 2001-07-24
DE69739277D1 (de) 2009-04-09
NO993257L (no) 1999-07-28
EP0966267B1 (de) 2009-02-25
AU725257B2 (en) 2000-10-12
AU4672397A (en) 1998-05-11
ES2321769T3 (es) 2009-06-10

Similar Documents

Publication Publication Date Title
ATE423547T1 (de) N-acyl-phosphatidylethanolamin-vermittelte wirkstoffdarreichung in liposomenform
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
IL140710A0 (en) Pulmonary delivery of active agents
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
FI954990A0 (fi) Aktiiviainetta sisältävä transdermaalinen valmiste
AU3559895A (en) Polyethylene glycol modified ceramide lipids and liposome uses thereof
DE69905170D1 (en) Thiazolopyrimidinderivate
SE9704546D0 (sv) Novel compounds
DE60138566D1 (en) Selbstformende thermodynamisch stabile liposome
BG104247A (en) Resorcinol derivatives
IL128801A0 (en) Combination of no synthase inhibitors and traps of reactive forms of oxygen
TR200100366T2 (tr) Aktif madde dağıtmaya mahsus bileşikler ve bileşimler.
TR199901077A2 (en) �spen�iyari form�lasyonlar.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
ES2108698T3 (es) Liposomas exentos de sustancias activas, para el tratamiento de aterosclerosis.
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
ES2071995T3 (es) Composicion para la activacion de macrofagia.
ATE345778T1 (de) (ester)-lysolecithine in liposomen
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
BR9714353A (pt) Sulfonil-benzazolonas
MX9705592A (es) Composiciones farmaceuticas que contienen corticosteroides y preparacion de las mismas.
MX9708111A (es) Lipidos cationicos para terapia genica.
ITRM980392A0 (it) Plasmide per la produzione di peptidi antimicrobici in batteri ricombinati

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties